Clinical Trial Update: Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase II trial evaluating gemcitabine in combination with Doxil for metastatic renal cell carcinoma has completed, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Doxil (liposomal doxorubicin)
• Gemzar (gemcitabine)

Snippet

Sponsor: University of Pittsburgh | Conditions: Metastatic Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-03-10